Xenetic (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology.
Framingham, MA
Joined May 2015
- Tweets1.3K
- Following719
- Followers3.6K
- Likes10
Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
bit.ly/4jXWFkS
$XBIO #SolidTumors #PancreaticCancer #CancerResearch
122
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
bit.ly/4zAqoVn
$XBIO #CancerResearch
84
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
bit.ly/4yxysps
$XBIO #BioDeal #BioTechDeal #PharmaDeal #NETs #NETTargeting #Sepsis #Lupus #Lymphoma
1
156
After years of research, a new drug, doraxiban, has been developed to help extend life expectancy for patients with pancreatic cancer.
We applaud this progress and continue to pursue technologies with the potential to further improve patient outcomes.
$XBIO
132
For patients with advanced pancreatic cancer, the five-year survival rate is approximately 3%.
Behind that number are patients, families and loved ones waiting for better options. $XBIO is working to advance new approaches where the need remains profound.
#PancreaticCancer
133
Approximately 62,000 people are diagnosed with pancreatic cancer each year in the U.S., and most are diagnosed at advanced stages when early detection is no longer feasible.
The need for innovative treatment approaches remains urgent.
$XBIO #PancreaticCancer #CancerResearch
163
Subscribe to Xenetic Biosciences’ email alerts for company announcements, research updates and key developments delivered to your inbox.
Sign up: bit.ly/3MTgAiR
$XBIO #Oncology #CancerResearch #Biotech
121
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
bit.ly/4z4Uf8T
$XBIO #Oncology #PancreaticCancer #PanCan #SolidTumors #HematologicalCancer
148
#InCaseYouMissedIt
$XBIO announced that its collaboration partner received Israeli Ministry of Health approval to begin a study evaluating DNase I with CAR-T therapy in large B-cell lymphoma.
Read more: bit.ly/4h0MJF
#CancerResearch #Biotech #DNase
188
Never miss an update from us.
Subscribe to our email alerts for the latest company information.
Sign up here: bit.ly/3MTgAiR
$XBIO #Oncology #PancreaticCancer #PanCan #SolidTumors #HematologicalCancer
1
111
Did you know?
Pancreatic cancer is the 3rd deadliest cancer in the U.S., with a 5-year survival rate of just ~3% for patients diagnosed at advanced stages.
These shows the urgent need for innovative new treatment options.
$XBIO #Oncology #PancreaticCancer #PanCan #SolidTumors
103
At Xenetic Biosciences, we are advancing innovative immune-oncology technologies designed to address hard-to-treat cancers.
Through our DNase platform, we are focused on improving treatment outcomes and advancing new possibilities for patients.
$XBIO #Oncology #PancreaticCancer
87
Today, we're celebrating 250 years of American independence and the freedom to pursue bold ideas, scientific discovery and a better future for patients.
From all of us at Xenetic Biosciences, we wish you a safe, happy and meaningful Fourth of July.
#IndependenceDay
1
71
We are a biopharmaceutical company focused on advancing proprietary technology platforms across multiple high-value cancer indications.
$XBIO #Oncology #PancreaticCancer #PanCan #SolidTumors #HematologicalCancer
131
Each year, ~67,000 people are diagnosed and nearly 52,000 lose their lives to Pancreatic Cancer in the U.S., a stark reminder of the urgent unmet need.
$XBIO is committed to advancing new approaches.
#Oncology #PancreaticCancer #PanCan #SolidTumors #HematologicalCancer
1
129
Don’t miss an update from Xenetic Biosciences.
Subscribe to email alerts for the latest on clinical progress, company news and key announcements straight to your inbox.
bit.ly/3MTgAiR
$XBIO #Oncology #PancreaticCancer #PanCan #SolidTumors #HematologicalCancer
1
74
June is #CancerSurvivorsMonth, a time to recognize and celebrate the millions of individuals whose journeys continue to inspire progress across cancer care and research.
At Xenetic, we remain committed to advancing innovative oncology approaches.
$XBIO #Oncology
1
90
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
bit.ly/4uejLF0
59
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
bit.ly/4fizOy3
$XBIO #PancreaticCancer #PanCan #CancerResearch
96
As a team, we’re committed to advancing research in pancreatic cancer, one of the most challenging diseases in oncology.
We believe that together, we can drive meaningful progress and make a real difference for patients.
$XBIO #PancreaticCancer #PanCan #CancerResearch
85